Initial burst of viremia related to CD8 effector memory T cells after living donor liver transplantation in hepatitis C virus-infected recipients

Translational Research : the Journal of Laboratory and Clinical Medicine
Yasutsugu TakadaShinji Uemoto

Abstract

The post-transplant immune responses, viremia, and allograft histology after living donor liver transplantation were studied in 39 hepatitis C virus (HCV)-infected recipients. The recipients were classified into the following groups according to a hierarchical clustering of their preoperative CD8CD45 T-cell isoforms: group I, naive-dominant; group II, effector memory-dominant; and group III, effector-dominant. Plasma HCV-RNA rapidly increased and then peaked as an initial burst around postoperative day (POD) 25 in group I, on POD 40 in group II, and on POD 55 in group III. The initial burst of viremia was suppressed by the high expression of CD8+CD28-CD27- subsets. The progression of fibrosis > or =F2 was significantly more frequent for those patients with the highest viremia levels. Moreover, the initial T-cell immune response became less important throughout time, and new immune responses emerged after 2 months that modified the host-virus interaction. It is suggested that the interferon (IFN)-alpha/ribavirin therapy starting 2 months may be an effective option and now is undertaken.

References

Mar 28, 1996·The New England Journal of Medicine·E J GaneR Williams
Oct 4, 1996·Science·J D AltmanM M Davis
Sep 18, 1997·The Journal of Experimental Medicine·A LalvaniA J McMichael
Sep 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M CharltonJ Hoofnagle
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M BerenguerJ Berenguer
Apr 3, 2002·Nature Medicine·Victor AppaySarah L Rowland-Jones
Feb 21, 2003·Nature·Edith M JanssenStephen P Schoenberger
Apr 12, 2003·Science·Joseph C Sun, Michael J Bevan
Apr 15, 2003·Clinics in Liver Disease·Hugo R Rosen
Oct 31, 2003·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Michael Charlton
Nov 24, 2004·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Norbert Hubert GruenerCarl Albrecht Schirren
Feb 16, 2005·Journal of Hepatology·David G Bowen, Christopher M Walker
Jul 11, 2006·Immunological Reviews·Douglas T FearonJames E D Thaventhiran
Mar 31, 2007·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Hiroto EgawaShinji Uemoto
Sep 1, 2007·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Hiroto EgawaKoichi Tanaka
Oct 30, 2008·European Journal of Immunology·Donatella CiuffredaValérie Dutoit
Jul 25, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A CarpentierN Delhem

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2021 Meta ULC. All rights reserved